%0 Journal Article
%T Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
%A Giandomenico Roviello
%A Giovanni Bozza
%A Giovanni Storto
%A Maria Grazia Rodriquenz
%A Michele Aieta
%A Rosj Gallicchio
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S174206
%X Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy
%K radium-223
%K pain
%K prostate cancer
%K radioactive therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301292/